Associated Papers
A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors.
Oh HC et al.
Genome Biology, 2026
Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma.
Matkar S et al.
Molecular Cancer Therapeutics, 2025
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Pathway-based, reaction-specific annotation of disease variants for elucidation of molecular phenotypes.
Orlic-Milacic M et al.
Database : the Journal of Biological Databases and Curation, 2024
Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.
Pucci P et al.
Nature Communications, 2024
Mining cancer genomes for change-of-metabolic-function mutations.
Tu KJ et al.
Communications Biology, 2023
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Berko ER et al.
Nature Communications, 2023
Genomic ALK alterations in primary and relapsed neuroblastoma.
Rosswog C et al.
British Journal of Cancer, 2023
Therapeutic Targeting of ALK in Neuroblastoma: Experience of Italian Precision Medicine in Pediatric Oncology.
Pastorino F et al.
Cancers, 2023
A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations.
Balasundaram A et al.
Frontiers in Molecular Biosciences, 2023
Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer.
Papageorgiou S et al.
Cancers, 2022
Integrated analysis of the clinical consequence and associated gene expression of ALK in ALK-positive human cancers.
Saifullah et al.
Heliyon, 2022
DrugCVar: a platform for evidence-based drug annotation for genetic variants in cancer.
Zhang X et al.
Bioinformatics (oxford, England), 2022
Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers.
Shukla N et al.
Nature Communications, 2022
From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma.
Decaesteker B et al.
Journal of Personalized Medicine, 2021
Mapping the Phospho-dependent ALK Interactome to Identify Novel Components in ALK Signaling.
Aboualizadeh F et al.
Journal of Molecular Biology, 2021
Chemical Genetics Screen Identifies COPB2 Tool Compounds That Alters ER Stress Response and Induces RTK Dysregulation in Lung Cancer Cells.
Saraon P et al.
Journal of Molecular Biology, 2021
Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection.
Thirunavukarasu D et al.
Genome Biology, 2021
TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations.
Murray BW et al.
Molecular Cancer Therapeutics, 2021
Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma.
Liu T et al.
Cold Spring Harbor Molecular Case Studies, 2021
Downregulation of PDGFRß Signaling Overcomes Crizotinib Resistance in a TYRO3 and ALK Mutated Neuroendocrine-Like Tumor.
Quinn CH et al.
Translational Oncology, 2021
Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation.
Patil K et al.
Proceedings of the National Academy of Sciences of the United States of America, 2021
Molecular targeting therapies for neuroblastoma: Progress and challenges.
Zafar A et al.
Medicinal Research Reviews, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Genetic Alterations Detected by Targeted Next-generation Sequencing and Their Clinical Implications in Neuroblastoma.
Koh KN et al.
Anticancer Research, 2020
Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors.
Li J et al.
Journal of Translational Medicine, 2020
Emerging Roles of ALK in Immunity and Insights for Immunotherapy.
Wang L et al.
Cancers, 2020
Standard operating procedure for curation and clinical interpretation of variants in cancer.
Danos AM et al.
Genome Medicine, 2019
Computational algorithms for in silico profiling of activating mutations in cancer.
Jordan EJ et al.
Cellular and Molecular Life Sciences : Cmls, 2019
Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma.
Janostiak R et al.
Iscience, 2019
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Shaw AT et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2019
Targeting anaplastic lymphoma kinase in neuroblastoma.
Umapathy G et al.
Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica, 2019
An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma.
Sano R et al.
Science Translational Medicine, 2019
Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.
Javanmardi N et al.
Scientific Reports, 2019
Reviving B-Factors: Activating ALK Mutations Increase Protein Dynamics of the Unphosphorylated Kinase.
Johnson TW et al.
Acs Medicinal Chemistry Letters, 2018
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.
Guan J et al.
Cold Spring Harbor Molecular Case Studies, 2018
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
The ALK receptor in sympathetic neuron development and neuroblastoma.
Janoueix-Lerosey I et al.
Cell and Tissue Research, 2018
Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480.
Gudernova I et al.
Oncotarget, 2017
Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis.
Uryu K et al.
Oncotarget, 2017
Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.
Wood AC et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.
Wang HQ et al.
Elife, 2017
Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib.
Muller IB et al.
Oncotargets and Therapy, 2017
Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM et al.
Plos Genetics, 2016
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.
Guan J et al.
Disease Models & Mechanisms, 2016
Insight into drug resistance mechanisms and discovery of potential inhibitors against wild-type and L1196M mutant ALK from FDA-approved drugs.
Li J et al.
Journal of Molecular Modeling, 2016